| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Jeffrey W Sherman is Director at XERS and has filed Form 4s across 2 companies. Jeffrey W Sherman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.3M at current prices.
Historically, Jeffrey W Sherman's trades have earned a middling insider score of 59/100 across 3 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +32.7%.
The biggest single holding is XERS (~$2.3M) as Director. The XERS filings lean toward selling, a net 36,832 shares.
Jeffrey W Sherman has 13 Form 4 filings on record from October 2021 to May 2026, across 2 companies: Director at Larimar Therapeutics (LRMR), 2023–2026; Director at Xeris Biopharma (XERS), 2021–2025.
The 22 reported transactions were 12 option or other derivative awards, 5 stock awards, 2 open-market purchases and 1 option exercise, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $35K and 1 sale worth about $335K.
The largest open-market purchase was 5,000 shares of LRMR at an average $5.00 on February 27, 2026, about $25K.
The only open-market sale was 42,232 shares of XERS at an average $7.92 on August 28, 2025, about $335K. Twelve months later XERS was up 7%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | LRMR Larimar Therapeutics, Inc. | Director | Buy | 5,000 | $5.00 | $25,000.00 | New | -34.4% | - | |
| Aug 28, 2025 | XERS Xeris Biopharma Holdings, Inc. | Director | Sale+OE | 42,232 | $7.92 | $334,515.45 | -16.2% | -9.1% | +7.3% | |
| Nov 27, 2023 | XERS Xeris Biopharma Holdings, Inc. | Director | Buy | 5,400 | $1.87 | $10,098.00 | New | +69.0% | +72.8% |